-$0.90 Earnings Per Share Expected for Insmed Incorporated (NASDAQ:INSM) This Quarter

Equities analysts forecast that Insmed Incorporated (NASDAQ:INSMGet Rating) will post earnings per share (EPS) of ($0.90) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Insmed’s earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.86). Insmed reported earnings per share of ($0.94) in the same quarter last year, which suggests a positive year-over-year growth rate of 4.3%. The company is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Insmed will report full-year earnings of ($3.56) per share for the current financial year, with EPS estimates ranging from ($3.82) to ($3.40). For the next year, analysts anticipate that the firm will post earnings of ($3.16) per share, with EPS estimates ranging from ($3.75) to ($1.85). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Insmed.

Insmed (NASDAQ:INSMGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The firm had revenue of $53.10 million during the quarter, compared to the consensus estimate of $53.36 million. Insmed had a negative return on equity of 108.20% and a negative net margin of 217.35%. The firm’s quarterly revenue was up 32.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.89) earnings per share.

A number of analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on Insmed in a research report on Wednesday, April 27th. They set a “buy” rating and a $56.00 price target on the stock. StockNews.com assumed coverage on Insmed in a research note on Thursday, March 31st. They set a “hold” rating for the company. SVB Leerink decreased their price target on Insmed from $57.00 to $52.00 and set an “outperform” rating for the company in a research note on Tuesday, February 22nd. Finally, Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $48.00.

In other Insmed news, Director Melvin Md Sharoky bought 20,000 shares of Insmed stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $17.20 per share, for a total transaction of $344,000.00. Following the completion of the acquisition, the director now directly owns 262,621 shares of the company’s stock, valued at $4,517,081.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO William Lewis sold 96,614 shares of the stock in a transaction on Wednesday, March 23rd. The shares were sold at an average price of $23.16, for a total value of $2,237,580.24. The disclosure for this sale can be found here. Company insiders own 4.63% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Spire Wealth Management purchased a new stake in shares of Insmed in the fourth quarter valued at $27,000. Point72 Hong Kong Ltd purchased a new stake in shares of Insmed during the fourth quarter worth $45,000. Advisor Group Holdings Inc. raised its holdings in shares of Insmed by 56.4% during the fourth quarter. Advisor Group Holdings Inc. now owns 2,140 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 772 shares in the last quarter. Lindbrook Capital LLC purchased a new stake in shares of Insmed during the fourth quarter worth $59,000. Finally, US Bancorp DE raised its holdings in shares of Insmed by 367.9% during the third quarter. US Bancorp DE now owns 2,569 shares of the biopharmaceutical company’s stock worth $70,000 after acquiring an additional 2,020 shares in the last quarter.

INSM traded up $1.00 on Friday, reaching $18.19. The company’s stock had a trading volume of 1,200,808 shares, compared to its average volume of 1,177,459. The business’s 50 day moving average is $22.86 and its 200 day moving average is $25.10. Insmed has a 1 year low of $16.41 and a 1 year high of $34.44. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -4.81 and a beta of 2.06. The company has a debt-to-equity ratio of 6.73, a current ratio of 6.04 and a quick ratio of 5.52.

About Insmed (Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.